{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:20:40Z","timestamp":1790727640194,"version":"4.1.0"},"reference-count":88,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Enzyme replacement therapy (ERT) has paved the way for treating the somatic symptoms of lysosomal storage diseases (LSDs), but the inability of intravenously administered enzymes to cross the blood\u2013brain barrier (BBB) has left the central nervous system (CNS)-related symptoms of LSDs largely impervious to the therapeutic benefits of ERT, although ERT via intrathecal and intracerebroventricular routes can be used for some neuronopathic LSDs (in particular, mucopolysaccharidoses). However, the considerable practical issues involved make these routes unsuitable for long-term treatment. Efforts have been made to modify enzymes (e.g., by fusing them with antibodies against innate receptors on the cerebrovascular endothelium) so that they can cross the BBB via receptor-mediated transcytosis (RMT) and address neuronopathy in the CNS. This review summarizes the various scientific and technological challenges of applying RMT to the development of safe and effective enzyme therapeutics for neuronopathic mucopolysaccharidoses; it then discusses the translational and methodological issues surrounding preclinical and clinical evaluation to establish RMT-applied ERT.<\/jats:p>","DOI":"10.3390\/pharmaceutics14061240","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T23:55:24Z","timestamp":1655078124000},"page":"1240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Treatment of Neuronopathic Mucopolysaccharidoses with Blood\u2013Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis"],"prefix":"10.3390","volume":"14","author":[{"given":"Hiroyuki","family":"Sonoda","sequence":"first","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Minami","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hirato","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairei","family":"So","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Tanizawa","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schmidt","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-8643","authenticated-orcid":false,"given":"Yuji","family":"Sato","sequence":"additional","affiliation":[{"name":"JCR Pharmaceuticals, Ashiya 659-0021, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sato, Y., Minami, K., Hirato, T., Tanizawa, K., Sonoda, H., and Schmidt, M. (2022). Drug delivery for neuronopathic lysosomal storage diseases: Evolving roles of the blood brain barrier and cerebrospinal fluid. Metab. Brain Dis.","DOI":"10.1007\/s11011-021-00893-3"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0271678X17732025","article-title":"Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases","volume":"38","author":"Wilhelm","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Leuthardt, E.C., Duan, C., Kim, M.J., Campian, J.L., Kim, A.H., Miller-Thomas, M.M., Shimony, J.S., and Tran, D.D. (2016). Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148613"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/s41467-018-04529-6","article-title":"Blood-brain barrier opening in Alzheimer\u2019s disease using MR-guided focused ultrasound","volume":"9","author":"Lipsman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1038\/s41467-019-12426-9","article-title":"First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound","volume":"10","author":"Abrahao","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/mt.2011.27","article-title":"Therapeutic potential of intracerebroventricular replacement of modified human beta-hexosaminidase B for GM2 gangliosidosis","volume":"19","author":"Matsuoka","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.conb.2018.12.014","article-title":"Transcytosis at the blood-brain barrier","volume":"57","author":"Ayloo","year":"2019","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mehta, A., and Winchester, B. (2012). Lysosomal Storage Disorders: A Practical Guide, Wiley-Blackwell.","DOI":"10.1002\/9781118514672"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: Lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pneurobio.2016.10.002","article-title":"Emerging therapies for neuropathic lysosomal storage disorders","volume":"152","author":"Kelly","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dmcn.13600","article-title":"Treatment strategies for lysosomal storage disorders","volume":"60","author":"Beck","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2352-4642(17)30087-1","article-title":"Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS","volume":"2","author":"Giugliani","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_17","unstructured":"Mehta, A., and Winchester, B. (2012). Central Nervous System Aspects, Neurodegeneration and the Blood-Brain Barrier. Lysosomal Storage Disorders: A Practical Guide, Wiley-Blackwell."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122S","author":"Scarpa","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of Intraventricular Cerliponase Alfa for CLN2 Disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pediatrneurol.2020.04.018","article-title":"Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics","volume":"110","author":"Lehwald","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtm.2021.02.018","article-title":"Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II","volume":"21","author":"Seo","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2021.03.002","article-title":"Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues","volume":"173","author":"Feldsien","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","article-title":"The role of brain barriers in fluid movement in the CNS: Is there a \u2018glymphatic\u2019 system?","volume":"135","author":"Abbott","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Abdul Razzak, R., Florence, G.J., and Gunn-Moore, F.J. (2019). Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123108"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sato, Y., and Okuyama, T. (2020). Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020400"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","article-title":"Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges","volume":"12","author":"Pulgar","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kouhi, A., Pachipulusu, V., Kapenstein, T., Hu, P., Epstein, A.L., and Khawli, L.A. (2021). Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126442"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/bit.21120","article-title":"Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier","volume":"96","author":"Boado","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.109.165092","article-title":"Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse","volume":"333","author":"Boado","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/bit.25289","article-title":"Insulin receptor antibody-iduronate 2-sulfatase fusion protein: Pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys","volume":"111","author":"Boado","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1073\/pnas.88.11.4771","article-title":"Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier","volume":"88","author":"Friden","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.brainres.2010.10.097","article-title":"Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein","volume":"1369","author":"Fu","year":"2011","journal-title":"Brain Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3892\/etm.2014.1727","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Yu","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eaay1163","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/07853890701214881","article-title":"The LDL receptor-related protein (LRP) family: An old family of proteins with new physiological functions","volume":"39","author":"May","year":"2007","journal-title":"Ann. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/1061186X.2016.1223676","article-title":"The potential use of rabies virus glycoprotein-derived peptides to facilitate drug delivery into the central nervous system: A mini review","volume":"25","author":"Huey","year":"2017","journal-title":"J. Drug Target."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41467-017-00952-3","article-title":"Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain","volume":"8","author":"Anraku","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/acsnano.9b09991","article-title":"Dual-Sensitive Nanomicelles Enhancing Systemic Delivery of Therapeutically Active Antibodies Specifically into the Brain","volume":"14","author":"Xie","year":"2020","journal-title":"ACS Nano"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1254\/fpj.21080","article-title":"[Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO((R)) I.V. Infusion 10 mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)]","volume":"157","author":"Yamamoto","year":"2022","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3389\/fnins.2019.01436","article-title":"Overview of Crosstalk Between Multiple Factor of Transcytosis in Blood Brain Barrier","volume":"13","author":"Tjakra","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e20211057","DOI":"10.1084\/jem.20211057","article-title":"Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme","volume":"219","author":"Arguello","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1134\/S2079086418020093","article-title":"Strategies for Modulation of Pharmacokinetics of Recombinant Therapeutic Proteins","volume":"8","author":"Zvonova","year":"2018","journal-title":"Biol. Bull. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-62703-586-6_7","article-title":"Humanization and simultaneous optimization of monoclonal antibody","volume":"1060","author":"Kuramochi","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.sbi.2016.12.005","article-title":"Protein engineering approaches for regulating blood-brain barrier transcytosis","volume":"45","author":"Goulatis","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Pardridge, W.M., and Chou, T. (2021). Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060535"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sade, H., Baumgartner, C., Hugenmatter, A., Moessner, E., Freskgard, P.O., and Niewoehner, J. (2014). A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096340"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuron.2016.03.013","article-title":"Fast, Temperature-Sensitive and Clathrin-Independent Endocytosis at Central Synapses","volume":"90","author":"Delvendahl","year":"2016","journal-title":"Neuron"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/0271678X221075967","article-title":"Hypoxemia increases blood-brain barrier permeability during extreme apnea in humans","volume":"42","author":"Bailey","year":"2022","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2045-8118-10-23","article-title":"Brain pericytes increase the lipopolysaccharide-enhanced transcytosis of HIV-1 free virus across the in vitro blood-brain barrier: Evidence for cytokine-mediated pericyte-endothelial cell crosstalk","volume":"10","author":"Dohgu","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"ref_57","first-page":"217","article-title":"A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery","volume":"20","author":"Muldoon","year":"1999","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2018.07.013","article-title":"Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS","volume":"125","author":"Tanaka","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ymthe.2021.01.027","article-title":"Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice","volume":"29","author":"Morimoto","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.ymgmr.2021.100758","article-title":"Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II","volume":"27","author":"Yamamoto","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_61","first-page":"534","article-title":"Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice","volume":"25","author":"Morimoto","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A Phase 2\/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil","volume":"29","author":"Giugliani","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Giugliani, R., Martins, A.M., Okuyama, T., Eto, Y., Sakai, N., Nakamura, K., Morimoto, H., Minami, K., Yamamoto, T., and Yamaoka, M. (2021). Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci., 22.","DOI":"10.20944\/preprints202109.0192.v1"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/bab.1617","article-title":"Progress in biopharmaceutical development","volume":"65","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_67","first-page":"372","article-title":"Antibody-mediated targeting of the transferrin receptor in cancer cells","volume":"73","author":"Helguera","year":"2016","journal-title":"Bol. Med. Hosp. Infant. Mex."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.molimm.2015.07.001","article-title":"Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1","volume":"67 Pt B","author":"Leoh","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Liu, R., Oldham, R.J., Teal, E., Beers, S.A., and Cragg, M.S. (2020). Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment. Antibodies, 9.","DOI":"10.3390\/antib9040064"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Van der Horst, H.J., Nijhof, I.S., Mutis, T., and Chamuleau, M.E.D. (2020). Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies. Cancers, 12.","DOI":"10.3390\/cancers12103041"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): An open label phase 1\u20132 trial","volume":"13","author":"Giugliani","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1124\/dmd.112.046375","article-title":"Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor","volume":"40","author":"Boado","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_73","unstructured":"Watts, R., and Ho, C. (2022, April 15). Interim Data from DNL310 Phase 1\/2 Hunter Syndrome Patient Study. Available online: https:\/\/www.denalitherapeutics.com\/sites\/default\/fles\/2021-09\/iMPS%20DNL310%20Webinar%20Final.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9554-7_1","article-title":"Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development","volume":"2011","author":"Kaffman","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.31887\/DCNS.2019.21.2\/pschulz","article-title":"Opportunities and challenges in psychopharmacology","volume":"21","author":"Schulz","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jpc.15796","article-title":"New hope for an old battle: Fighting Hunter disease","volume":"58","author":"Daher","year":"2022","journal-title":"J. Paediatr. Child Health"},{"key":"ref_77","unstructured":"Bowlby, J. (1969). Attachment, Basic Books. [2nd ed.]."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-8118-8-7","article-title":"Drug transport in brain via the cerebrospinal fluid","volume":"8","author":"Pardridge","year":"2011","journal-title":"Fluids Barriers CNS"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10928-021-09800-w","article-title":"Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system","volume":"49","author":"Chang","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13023-020-1332-x","article-title":"A roadmap to using historical controls in clinical trials\u2014by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)","volume":"15","author":"Ghadessi","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: A review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10545-016-9917-1","article-title":"The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders","volume":"39","author":"Broomfield","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/01.HYP.12.3.223","article-title":"Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment","volume":"12","author":"Laragh","year":"1988","journal-title":"Hypertension"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40259-017-0248-z","article-title":"Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology","volume":"31","author":"Pardridge","year":"2017","journal-title":"Biodrugs"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Parini, R., and Deodato, F. (2020). Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082975"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/6\/1240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:07Z","timestamp":1760138887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/6\/1240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":88,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["pharmaceutics14061240"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14061240","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,11]]}}}